DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Velcade (Bortezomib) - Thrombocytopenia - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Thrombocytopenia (100)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Velcade (Bortezomib) where reactions include thrombocytopenia. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 100   Next >>

Possible Velcade side effects in male

Reported by a physician from Germany on 2012-08-24

Patient: male

Reactions: Portal Hypertension, Pain, Thrombocytopenia, Epistaxis, Decreased Appetite, Renal Failure Acute, Bronchopulmonary Aspergillosis, Pseudomonas Infection, Anaemia, Hyperviscosity Syndrome, Rash, Haemangioma of Spleen, Pulmonary Sepsis, Syncope, Respiratory Failure, Visual Impairment, Leukopenia

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Cotrim DS
    Indication: Product Used FOR Unknown Indication

Dexamethasone Sodium Phosphate
    Indication: Multiple Myeloma
    Start date: 2012-03-21
    End date: 2012-04-01

Dexamethasone Sodium Phosphate
    Start date: 2012-03-01
    End date: 2012-03-12

Dexamethasone Sodium Phosphate
    Start date: 2012-05-21
    End date: 2012-06-10

Dexamethasone Sodium Phosphate
    Start date: 2012-04-17
    End date: 2012-04-28

Doxorubicin HCL
    Indication: Multiple Myeloma
    Start date: 2012-03-21
    End date: 2012-04-01

Doxorubicin HCL
    Start date: 2012-04-17
    End date: 2012-04-28

Lenalidomide
    Indication: Multiple Myeloma
    Start date: 2012-05-21
    End date: 2012-06-10

Velcade
    Indication: Multiple Myeloma
    Start date: 2012-04-17
    End date: 2012-04-28

Velcade
    Start date: 2012-03-21
    End date: 2012-04-01

Velcade
    Start date: 2012-03-01
    End date: 2012-03-12

Other drugs received by patient: Acyclovir



Possible Velcade side effects in

Reported by a physician from France on 2012-08-23

Patient:

Reactions: Back Pain, Electrocardiogram QT Prolonged, Dyspnoea, Hypotension, Thrombocytopenia

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Dexamethasone
    Dosage: 20 mg, unk
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2012-05-22
    End date: 2012-05-29

JNJ-26481585
    Dosage: 12 mg, unk
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2012-05-21
    End date: 2012-05-31

Velcade
    Dosage: 2.1 mg, unk
    Indication: Multiple Myeloma
    Start date: 2012-05-22
    End date: 2012-05-29

Other drugs received by patient: Ceftriaxone; Primperan / 00041901 /; Acetaminophen; Zelitrex / 01269701 /; Fentanyl; Atracurium Besylate; Kardegic / 00002703 /; Oxycontin; Oxygen; Tranxene; Primperan / 00041901 /; Bumetanide; Crestor; Primperan / 00041901 /; Hydrocortisone; Ondansetron; Ondansetron; Ondansetron; Importal; Tramadol HCL; Noradrenaline / 00127501 /; Tramadol HCL; Morphine; Furosemide; Midazolam; Tramadol HCL



Possible Velcade side effects in 70 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-22

Patient: 70 year old male, weighing 104.3 kg (229.5 pounds)

Reactions: Pneumonia, Thrombocytopenia, Groin Pain

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Torisel
    Dosage: 25 mg d1, d8 iv
    Indication: Chronic Lymphocytic Leukaemia
    Start date: 2012-07-30
    End date: 2012-08-06

Velcade
    Dosage: 3.6 mg d1, d8 iv
    Indication: Chronic Lymphocytic Leukaemia
    Start date: 2012-07-30
    End date: 2012-08-06



Possible Velcade side effects in male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-22

Patient: male, weighing 86.2 kg (189.6 pounds)

Reactions: Vomiting, Nausea, Hypotension, Systemic Inflammatory Response Syndrome, Pyrexia, Thrombocytopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Velcade



Possible Velcade side effects in

Reported by a physician from France on 2012-08-21

Patient:

Reactions: Overdose, Thrombocytopenia

Drug(s) suspected as cause:
Dexamethasone
    Dosage: 10 mg, unk
    Indication: Multiple Myeloma
    Start date: 2012-01-23
    End date: 2012-08-03

Revlimid
    Dosage: 25 mg, unk
    Indication: Multiple Myeloma
    Start date: 2012-01-23
    End date: 2012-08-05

Velcade
    Dosage: unk mg, unk
    Indication: Multiple Myeloma
    Start date: 2012-01-23

Velcade
    Dosage: 1 unk, unk
    Start date: 2012-03-01
    End date: 2012-08-02

Other drugs received by patient: Amoxicillin; Innohep; Morphine Sulfate; Nexium; Xatral / 00975301 /; Potassium Chloride; Bactrim; Lexomil



Possible Velcade side effects in

Reported by a physician from Greece on 2012-08-21

Patient:

Reactions: Thrombocytopenia

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Velcade



Possible Velcade side effects in

Reported by a physician from Italy on 2012-08-20

Patient:

Reactions: Dyspnoea, Anaemia, Pancytopenia, Thrombocytopenia, Asthenia

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Velcade

Other drugs received by patient: Nitroglycerin; Bisoprolol Fumarate; Dexamethasone; Furosemide; Lasix; Dexamethasone



Possible Velcade side effects in

Reported by a physician from Turkey on 2012-08-20

Patient:

Reactions: Pneumonia, Thrombocytopenia

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Dexamethasone
    Dosage: 20 mg, unk
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2009-02-09
    End date: 2009-04-20

Velcade
    Dosage: 2.57 mg, unk
    Indication: Multiple Myeloma
    Start date: 2009-02-09
    End date: 2009-04-20



Possible Velcade side effects in

Reported by a physician from United States on 2012-08-17

Patient:

Reactions: Vomiting, Cardio-Respiratory Arrest, International Normalised Ratio Increased, Thrombocytopenia

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Dexamethasone
    Dosage: 20 mg, unk
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2012-07-03
    End date: 2012-07-14

Velcade
    Dosage: 1.3 mg, unk
    Indication: Multiple Myeloma
    Start date: 2012-07-03
    End date: 2012-07-13

Other drugs received by patient: Carvedilol; Omeprazole; Calcium; Acenocoumarol; Candesartan Cilexetil; Prednisone TAB; Furosemide; Folic Acid; Movicol / 01053601 /



Possible Velcade side effects in

Reported by a physician from United States on 2012-08-16

Patient:

Reactions: Nausea, Pain, Motor Dysfunction, Rash, Peripheral Sensory Neuropathy, Fatigue, Blood Potassium Decreased, Dyspepsia, Diarrhoea, Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin HCL
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1
    Indication: Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin HCL
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: B-Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Waldenstrom's Macroglobulinaemia

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: non-Hodgkin's Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphocytic Lymphoma

Rituximab
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance
    Indication: Lymphocytic Lymphoma

Rituximab
    Dosage: maintenance
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: maintenance
    Indication: Lymphoma

Rituximab
    Dosage: on day 1

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: B-Cell Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Waldenstrom's Macroglobulinaemia

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: Lymphocytic Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Waldenstrom's Macroglobulinaemia

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: B-Cell Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphocytic Lymphoma

Other drugs received by patient: Acetaminophen; Diphenhydramine Hydrochloride; Ondansetron



Possible Velcade side effects in

Reported by a physician from France on 2012-08-16

Patient:

Reactions: Electrocardiogram QT Prolonged, Back Pain, Dyspnoea, Hypotension, Thrombocytopenia

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Dexamethasone
    Dosage: 20 mg, unk
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2012-05-22
    End date: 2012-05-29

JNJ-26481585
    Dosage: 12 mg, unk
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2012-05-21
    End date: 2012-05-31

Velcade
    Dosage: 2.1 mg, unk
    Indication: Multiple Myeloma
    Start date: 2012-05-22
    End date: 2012-05-29

Other drugs received by patient: Ceftriaxone; Primperan / 00041901 /; Bumetanide; Acetaminophen; Morphine; Atracurium Besylate; Ondansetron; Crestor; Fentanyl; Furosemide; Midazolam; Tranxene; Ondansetron; Tramadol HCL; Noradrenaline / 00127501 /; Hydrocortisone; Importal; Tramadol HCL; Kardegic / 00002703 /; Primperan / 00041901 /; Primperan / 00041901 /; Tramadol HCL; Zelitrex / 01269701 /; Oxycontin; Oxygen; Ondansetron



Possible Velcade side effects in

Reported by a health professional (non-physician/pharmacist) from France on 2012-08-10

Patient:

Reactions: Off Label Use, Chest Pain, Thrombocytopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Velcade

Other drugs received by patient: Oxazepam; Acebutolol; Ramipril; Kardegic / 00002703 /; Zolpidem; Flecainide Acetate; Dafalgan / 00020001 /



Possible Velcade side effects in male

Reported by a physician from Germany on 2012-08-07

Patient: male

Reactions: Portal Hypertension, Pain, Thrombocytopenia, Decreased Appetite, Renal Failure Acute, Epistaxis, Bronchopulmonary Aspergillosis, Pseudomonas Infection, Anaemia, Hyperviscosity Syndrome, Rash, Pulmonary Sepsis, Haemangioma of Spleen, Syncope, Respiratory Failure, Visual Impairment, Leukopenia

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Cotrim DS
    Indication: Product Used FOR Unknown Indication

Dexamethasone Sodium Phosphate
    Start date: 2012-05-21
    End date: 2012-06-10

Dexamethasone Sodium Phosphate
    Indication: Multiple Myeloma
    Start date: 2012-04-17
    End date: 2012-04-28

Dexamethasone Sodium Phosphate
    Start date: 2012-03-01
    End date: 2012-03-12

Dexamethasone Sodium Phosphate
    Start date: 2012-03-21
    End date: 2012-04-01

Doxorubicin HCL
    Indication: Multiple Myeloma
    Start date: 2012-04-17
    End date: 2012-04-28

Doxorubicin HCL
    Start date: 2012-03-21
    End date: 2012-04-01

Lenalidomide
    Indication: Multiple Myeloma
    Start date: 2012-05-21
    End date: 2012-06-10

Velcade
    Indication: Multiple Myeloma
    Start date: 2012-03-01
    End date: 2012-03-12

Velcade
    Start date: 2012-04-17
    End date: 2012-04-28

Velcade
    Start date: 2012-03-21
    End date: 2012-04-01

Other drugs received by patient: Acyclovir



Possible Velcade side effects in

Reported by a physician from Netherlands on 2012-08-07

Patient:

Reactions: Diabetes Mellitus, Thrombocytopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: unk
    Indication: Multiple Myeloma
    Start date: 2012-07-16

Dexamethasone
    Dosage: unk
    Indication: Multiple Myeloma
    Start date: 2012-07-16

Velcade
    Dosage: unk
    Indication: Multiple Myeloma
    Start date: 2012-07-16

Other drugs received by patient: Omeprazole; Fluconazole; Zelitrex / 01269701 /; Ciproxin / 00697201 /; Metoclopramide



Possible Velcade side effects in

Reported by a physician from Japan on 2012-08-06

Patient:

Reactions: Disseminated Intravascular Coagulation, Neutropenia, Gastric Ulcer, Thrombocytopenia, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Melphalan Hydrochloride
    Dosage: 8 mg, unk
    Indication: Multiple Myeloma
    Start date: 2012-04-24
    End date: 2012-04-28

Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: Multiple Myeloma
    Start date: 2012-03-29
    End date: 2012-06-21

Other drugs received by patient: Zometa; Prednisolone; Loxoprofen; Dexamethasone



Possible Velcade side effects in male

Reported by a physician from Germany on 2012-08-06

Patient: male

Reactions: Portal Hypertension, Pain, Thrombocytopenia, Epistaxis, Decreased Appetite, Renal Failure Acute, Bronchopulmonary Aspergillosis, Anaemia, Pseudomonas Infection, Hyperviscosity Syndrome, Rash, Pulmonary Sepsis, Haemangioma of Spleen, Syncope, Respiratory Failure, Visual Impairment, Leukopenia

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Cotrim DS
    Indication: Product Used FOR Unknown Indication

Dexamethasone Sodium Phosphate
    Indication: Multiple Myeloma
    Start date: 2012-04-17
    End date: 2012-04-28

Dexamethasone Sodium Phosphate
    Start date: 2012-03-21
    End date: 2012-04-01

Dexamethasone Sodium Phosphate
    Start date: 2012-05-21
    End date: 2012-06-10

Dexamethasone Sodium Phosphate
    Start date: 2012-03-01
    End date: 2012-03-12

Doxorubicin HCL
    Start date: 2012-03-21
    End date: 2012-04-01

Doxorubicin HCL
    Indication: Multiple Myeloma
    Start date: 2012-04-17
    End date: 2012-04-28

Lenalidomide
    Indication: Multiple Myeloma
    Start date: 2012-05-21
    End date: 2012-06-10

Velcade
    Indication: Multiple Myeloma
    Start date: 2012-03-01
    End date: 2012-03-12

Velcade
    Start date: 2012-04-17
    End date: 2012-04-28

Velcade
    Start date: 2012-03-21
    End date: 2012-04-01

Other drugs received by patient: Acyclovir



Possible Velcade side effects in

Reported by a physician from Korea, Republic of on 2012-08-02

Patient:

Reactions: Pneumonia, Neutropenia, Thrombocytopenia, Septic Shock

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Melphalan Hydrochloride
    Dosage: 18 mg/m2, unk
    Indication: Multiple Myeloma
    Start date: 2012-01-27
    End date: 2012-01-30

Melphalan Hydrochloride
    Dosage: 11 mg/m2, unk
    Start date: 2012-03-22
    End date: 2012-03-25

Prednisolone
    Dosage: 58 mg/m2, unk
    Indication: Multiple Myeloma
    Start date: 2012-01-27
    End date: 2012-01-30

Velcade
    Dosage: 1.3 mg/m2, unk
    Indication: Multiple Myeloma
    Start date: 2012-01-27
    End date: 2012-04-01



Possible Velcade side effects in

Reported by a physician from United States on 2012-08-01

Patient:

Reactions: Nausea, Motor Dysfunction, Pain, Rash, Peripheral Sensory Neuropathy, Fatigue, Dyspepsia, Blood Potassium Decreased, Diarrhoea, Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Cyclophosphamide
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Cyclophosphamide
    Dosage: on day 1

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: B-Cell Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Waldenstrom's Macroglobulinaemia

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphocytic Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: maintenance
    Indication: Waldenstrom's Macroglobulinaemia

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1
    Indication: Lymphoma

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: non-Hodgkin's Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: B-Cell Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: Lymphocytic Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Waldenstrom's Macroglobulinaemia

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Waldenstrom's Macroglobulinaemia

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphocytic Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: B-Cell Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphoma

Other drugs received by patient: Diphenhydramine HCL; Acetaminophen; Ondansetron



Possible Velcade side effects in

Reported by a health professional (non-physician/pharmacist) from France on 2012-07-31

Patient:

Reactions: Mantle Cell Lymphoma Refractory, Skin Toxicity, Neurotoxicity, Neuropathy Peripheral, Hepatotoxicity, Cardiotoxicity, Thrombocytopenia, Renal Disorder, Drug Effect Decreased, Gastrointestinal Toxicity, Anaemia, Febrile Neutropenia, Toxicity To Various Agents, Mantle Cell Lymphoma, Lung Disorder, Neutropenia, Infection

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Chlorambucil
    Dosage: from day 20 to 29.
    Indication: Mantle Cell Lymphoma

Dexamethasone
    Dosage: day 1 to 4
    Indication: Mantle Cell Lymphoma

Doxorubicin Hydrochloride
    Dosage: as a continuous infusion from day 1 to 4

Doxorubicin Hydrochloride
    Dosage: as a continuous infusion from day 1 to 4
    Indication: Mantle Cell Lymphoma

Rituximab
    Dosage: on day 1 (and day 8 of cycle 1)
    Indication: Mantle Cell Lymphoma

Velcade
    Dosage: on days 1, 4, 8 and 11
    Indication: Mantle Cell Lymphoma



Possible Velcade side effects in

Reported by a physician from Japan on 2012-07-23

Patient:

Reactions: Pneumonia, C-Reactive Protein Increased, Dehydration, Atrial Fibrillation, Thrombocytopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Dexamethasone
    Dosage: 20 mg, unk
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2012-03-12

Panobinostat
    Dosage: 20 mg, unk
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2012-03-12

Velcade
    Dosage: 2.3 mg, unk
    Indication: Multiple Myeloma
    Start date: 2012-03-12

Other drugs received by patient: Amlodipine; Candesartan Cilexetil; Mucosta; Warfarin Sodium



Possible Velcade side effects in

Reported by a health professional (non-physician/pharmacist) from France on 2012-07-19

Patient:

Reactions: Mantle Cell Lymphoma Refractory, Skin Toxicity, Neurotoxicity, Neuropathy Peripheral, Hepatotoxicity, Cardiotoxicity, Thrombocytopenia, Drug Effect Decreased, Renal Disorder, Gastrointestinal Toxicity, Anaemia, Febrile Neutropenia, Toxicity To Various Agents, Mantle Cell Lymphoma, Lung Disorder, Neutropenia, Infection

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Chlorambucil
    Dosage: from day 20 to 29.
    Indication: Mantle Cell Lymphoma

Dexamethasone
    Dosage: day 1 to 4
    Indication: Mantle Cell Lymphoma

Doxorubicin HCL
    Dosage: as a continuous infusion from day 1 to 4
    Indication: Mantle Cell Lymphoma

Rituximab
    Dosage: on day 1 (and day 8 of cycle 1)
    Indication: Mantle Cell Lymphoma

Velcade
    Dosage: on days 1, 4, 8 and 11
    Indication: Mantle Cell Lymphoma



Possible Velcade side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-18

Patient:

Reactions: Pneumonia, Nausea, Lymphopenia, Hyperglycaemia, Anaemia, Febrile Neutropenia, Constipation, Renal Failure, Neuropathy Peripheral, Fatigue, Diarrhoea, Embolism, Neutropenia, Thrombocytopenia, Deep Vein Thrombosis

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 500 milligram/sq. meter
    Indication: Multiple Myeloma

Dexamethasone
    Dosage: 40 milligram
    Indication: Multiple Myeloma

Revlimid
    Dosage: 25 milligram
    Administration route: Oral
    Indication: Multiple Myeloma

Revlimid
    Dosage: 15 milligram
    Administration route: Oral

Velcade
    Dosage: 1.3 milligram/sq. meter
    Indication: Multiple Myeloma

Velcade
    Dosage: 1.3 milligram/sq. meter



Possible Velcade side effects in

Reported by a physician from Japan on 2012-07-17

Patient:

Reactions: Pneumonia, Pain, Atrial Fibrillation, Interstitial Lung Disease, C-Reactive Protein Increased, Dehydration, Dizziness, Thrombocytopenia, Decreased Appetite, Infection Susceptibility Increased

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Dexamethasone
    Dosage: 20 mg, unk
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2012-03-12

Panobinostat
    Dosage: 20 mg, unk
    Administration route: Oral
    Indication: Multiple Myeloma
    Start date: 2012-03-12

Velcade
    Dosage: 2.3 mg, unk
    Indication: Multiple Myeloma
    Start date: 2012-03-12

Other drugs received by patient: Amlodipine; Candesartan Cilexetil; Warfarin Sodium; Mucosta



Possible Velcade side effects in male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-16

Patient: male, weighing 86.2 kg (189.6 pounds)

Reactions: Vomiting, Nausea, Hypotension, Systemic Inflammatory Response Syndrome, Pyrexia, Thrombocytopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Velcade
    Dosage: 1.3 mg/m2, cyclic
    Indication: Multiple Myeloma
    Start date: 2012-04-17
    End date: 2012-04-24

Velcade
    Dosage: 2.3 mg, unk
    Start date: 2012-05-04



Possible Velcade side effects in

Reported by a physician from Japan on 2012-07-12

Patient:

Reactions: Disseminated Intravascular Coagulation, Neutropenia, Gastric Ulcer, Thrombocytopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Velcade

Other drugs received by patient: Melphalan Hydrochloride; Zometa; Loxoprofen; Prednisolone; Dexamethasone



Possible Velcade side effects in 61 year old female

Reported by a physician from United States on 2012-07-11

Patient: 61 year old female, weighing 61.4 kg (135.1 pounds)

Reactions: Anaemia, Chills, Febrile Neutropenia, Thrombocytopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Dexamethasone
    Dosage: day of and after velcade
    Indication: Multiple Myeloma
    Start date: 2012-07-02
    End date: 2012-07-03

Revlimid
    Dosage: days 1-14
    Indication: Multiple Myeloma
    Start date: 2012-07-02
    End date: 2012-07-03

Velcade
    Dosage: days 1, 4, 8, 11
    Indication: Multiple Myeloma
    Start date: 2012-07-02
    End date: 2012-07-02

Other drugs received by patient: Prilosec; Lovenox; Acyclovir



Possible Velcade side effects in

Reported by a consumer/non-health professional from United States on 2012-07-09

Patient:

Reactions: Dyspnoea, Anaemia, General Physical Health Deterioration, Oesophageal Haemorrhage, Thrombocytopenia, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Dexamethasone
    Dosage: 8 mg, cyclic
    Indication: Multiple Myeloma
    Start date: 2010-08-30
    End date: 2011-11-04

Doxorubicin HCL
    Dosage: 9 mg/m2, cyclic
    Indication: Multiple Myeloma
    Start date: 2011-08-30
    End date: 2011-11-04

Velcade
    Dosage: 1.3 mg, cyclic
    Indication: Multiple Myeloma
    Start date: 2011-08-30
    End date: 2011-11-04

Other drugs received by patient: Moxonidin; Amlodipine; Finasterid Orion; Metoprolol Tartrate; Ramipril; Allopurinol; Levothyroxine Sodium; Calcivit D; Pantozol / 01263202 /; Hydromorphone HCL; Decostriol; Prednisone TAB; Tamsulosin HCL; Torsemide; Folsan



Possible Velcade side effects in male

Reported by a pharmacist from Netherlands on 2012-07-06

Patient: male, weighing 80.0 kg (176.0 pounds)

Reactions: Colitis, Thrombocytopenia, Leukopenia, Renal Failure Acute

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Multiple Myeloma
    Start date: 2012-05-04

Velcade
    Indication: Multiple Myeloma
    Start date: 2012-05-04

Other drugs received by patient: Fluconazole; Valaciclovir; Dexamethasone; Cotrim



Possible Velcade side effects in

Reported by a pharmacist from Netherlands on 2012-07-06

Patient:

Reactions: Diarrhoea, Oliguria, Colitis, Pyrexia, Thrombocytopenia, Leukopenia, Renal Failure Acute

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Velcade

Other drugs received by patient: Valaciclovir; Cyclophosphamide; Fluconazole; Cotrim; Dexamethasone



Possible Velcade side effects in

Reported by a physician from United States on 2012-07-05

Patient:

Reactions: Nausea, Anaemia, Chills, Constipation, Fatigue, Neuropathy Peripheral, Alopecia, Adverse Event, Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Cyclophosphamide

Cyclophosphamide
    Indication: Chronic Lymphocytic Leukaemia

Cyclophosphamide
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1
    Indication: Chronic Lymphocytic Leukaemia

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: B-Cell Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Chronic Lymphocytic Leukaemia

Prednisone
    Dosage: on days 1-5
    Administration route: Oral

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1
    Indication: Chronic Lymphocytic Leukaemia

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance

Velcade
    Dosage: on days 1 and 8

Velcade
    Dosage: on days 1 and 8
    Indication: Chronic Lymphocytic Leukaemia

Velcade
    Dosage: on days 1 and 8
    Indication: B-Cell Lymphoma



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017